Gilead Sciences (NASDAQ:GILD) Given New $170.00 Price Target at Mizuho

Gilead Sciences (NASDAQ:GILD) had its target price raised by Mizuho from $140.00 to $170.00 in a research note published on Wednesday morning,MarketScreener reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Needham & Company LLC boosted their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Scotiabank boosted their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Finally, UBS Group upped their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Twenty-three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.21.

Gilead Sciences Price Performance

GILD opened at $151.06 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. The stock has a market capitalization of $187.41 billion, a P/E ratio of 22.36, a price-to-earnings-growth ratio of 2.06 and a beta of 0.36. The company’s 50 day simple moving average is $132.29 and its 200-day simple moving average is $123.18. Gilead Sciences has a one year low of $93.37 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s payout ratio is presently 46.68%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares in the company, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the sale, the chief executive officer owned 613,912 shares in the company, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 319,891 shares of company stock valued at $45,091,556 over the last ninety days. 0.27% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Brighton Jones LLC lifted its stake in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $215,000. Sivia Capital Partners LLC lifted its position in shares of Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares in the last quarter. Brookstone Capital Management boosted its holdings in Gilead Sciences by 3.2% during the second quarter. Brookstone Capital Management now owns 123,288 shares of the biopharmaceutical company’s stock worth $13,669,000 after purchasing an additional 3,848 shares during the last quarter. Finally, Cookson Peirce & Co. Inc. bought a new position in Gilead Sciences in the second quarter valued at $319,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target to $170 and kept a Buy rating, signaling meaningful analyst upside vs. the recent price and supporting potential buying interest. Rothschild PT Raise
• Positive Sentiment: Gilead’s reported Q4 beat and reiterated FY26 EPS guidance, coupled with reported progress in the HIV franchise and a Yescarta label shift, bolster the investment thesis of steady HIV cash flows plus potential CAR‑T upside. HIV & Yescarta Article
• Positive Sentiment: Gilead recently raised its quarterly dividend to $0.82 (from $0.79), increasing yield and returning more cash to shareholders — supportive for income-focused investors. MarketBeat Summary
• Neutral Sentiment: Maxim Group reiterated a Hold rating, noting HIV growth may be largely priced in and diversification still looks limited — a caution that tempers near-term upside. TipRanks / Hold Rating
• Neutral Sentiment: Analyst Q&A and earnings‑call coverage highlight pipeline timing, margins and guidance drivers — useful context for positioning but mixed in directional impact. Earnings Call Questions
• Neutral Sentiment: Retrospective pieces on multi‑year returns (e.g., Benzinga) are informative for retail holders but unlikely to move price materially. Benzinga Performance Piece
• Negative Sentiment: CFO Andrew D. Dickinson sold 3,000 shares at about $154.43 (Form 4 filing). Even routine insider sales can sap near‑term sentiment, particularly alongside other insider moves. CFO Form 4
• Negative Sentiment: Significant insider sale by Johanna Mercier: 28,000 shares sold at ~ $154.44 (an ~18.9% reduction in her holding). That larger leadership sale is likely the primary driver of today’s negative sentiment and selling pressure. Mercier Form 4

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.